• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Mol Med . Entangling COVID-19 Associated Thrombosis Into a Secondary Antiphospholipid Antibody Syndrome: Diagnostic and Therapeutic Perspectiv

tetano

Editor, Senior Moderator
Int J Mol Med


. 2020 Jun 25.
doi: 10.3892/ijmm.2020.4659. Online ahead of print.
Entangling COVID-19 Associated Thrombosis Into a Secondary Antiphospholipid Antibody Syndrome: Diagnostic and Therapeutic Perspectives (Review)


Eugenio Cavalli[SUP] 1 [/SUP], Alessia Bramanti[SUP] 2 [/SUP], Rosella Ciurleo[SUP] 2 [/SUP], Andrey I Tchorbanov[SUP] 3 [/SUP], Antonio Giordano[SUP] 4 [/SUP], Paolo Fagone[SUP] 1 [/SUP], Cristina Belizna[SUP] 5 [/SUP], Placido Bramanti[SUP] 2 [/SUP], Yehuda Shoenfeld[SUP] 6 [/SUP], Ferdinando Nicoletti[SUP] 1 [/SUP]



Affiliations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel β coronavirus that is the etiological agent of the pandemic coronavirus disease 2019 (COVID‑19) that at the time of writing (June 16, 2020) has infected almost 6 million people with some 450,000 deaths. These numbers are still rising daily. Most (some 80%) cases of COVID‑19 infection are asymptomatic, a substantial number of cases (15%) require hospitalization and an additional fraction of patients (5%) need recovery in intensive care units. Mortality for COVID‑19 infection appears to occur globally between 0.1 and 0.5% of infected patients although the frequency of lethality is significantly augmented in the elderly and in patients with other comorbidities. The development of acute respiratory distress syndrome and episodes of thromboembolism that may lead to disseminated intravascular coagulation (DIC) represent the primary causes of lethality during COVID‑19 infection. Increasing evidence suggests that thrombotic diathesis is due to multiple derangements of the coagulation system including marked elevation of D‑dimer that correlate negatively with survival. We propose here that the thromboembolic events and eventually the development of DIC provoked by SARS‑CoV‑2 infection may represent a secondary anti‑phospholipid antibody syndrome (APS). We will apply both Baconian inductivism and Cartesian deductivism to prove that secondary APS is likely responsible for coagulopathy during the course of COVID‑19 infection. Diagnostic and therapeutic implications of this are also discussed.
 
Back
Top Bottom